Drugs · acquisition-cost intelligence
venlafaxine
· ingredient venlafaxine· VENLAFAXINE BESYLATE MONOHYDRATE 112.5 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$6.17
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other venlafaxine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| venlafaxine | $0.07973 | −$6.09 |
| venlafaxine | $0.08119 | −$6.09 |
| Effexor XR | $0.08650 | −$6.09 |
| Venlafaxine Hydrochloride | $0.26390 | −$5.91 |
| venlafaxine hydrochloride | $0.52931 | −$5.64 |
Medicare Part D coverage · CY2026
On 85 plan formularies · typical tier 4
Prior auth 1% · Step therapy 6% · Quantity limit 87% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.